Inozyme Pharma (INZY.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Jun20

Inozyme Pharma Postpones Shareholders' Meeting Due to Acquisition

21:01

May19

FactSet Analysts Give Inozyme Pharma Hold Rating, Price Target of $6.86

11:47

Piper Sandler Downgrades Inozyme Pharma Inc to Neutral

03:18

UBS downgrades INOZYME PHARMA INC rating to neutral

03:14

May16

BioMarin Pharmaceuticals Acquires Inozyme Pharma

11:38

May15

Inozyme Pharma released FY2025 Q1 earnings on May 14 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4362 (forecast USD -0.3985)

03:00

Schedules & Filings

Schedules

Filings

May14

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -28.04 M, EPS -0.4362

Mar10

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Net Income -27.07 M, EPS -0.4214

Nov5

Earning Release(EST)

FY2024 Q3 Earning Release (USD) Net Income -24.57 M, EPS -0.3882

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change